Skip to content
Pharma Observatory a Scientist.com platform

Organization (Hospital)

Instituto de Olhos de Goiânia

ClinicalTrials.gov lists Instituto de Olhos de Goiânia as lead sponsor of 27 trials. It has 10 approved assets.

BR Hospital
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

5 0 1996 2026

Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.

2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.

This page covers Instituto de Olhos de Goiânia: 27 lead-sponsored trials and 1 legal-entity registration.

Get the Instituto de Olhos de Goiânia report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Disease areas (14)

Shown in this order: most trials first.

Disease areas
Disease area Trials
Myopia 5
Neovascularization, Pathologic 4
Glaucoma 3
Astigmatism 2
Macular Degeneration 2

Showing 5 of 14 disease areas.

Start your 14-day trial Email me all 14 disease areas as a PDF

Trials by start year as sponsor or collaborator (13)

Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Show the table of trials by start year as sponsor or collaborator
Trials by start year as sponsor or collaborator
Year Trials started
2017 5
2016 1
2015 2
2014 2
2013 2
2012 2
2010 2
2009 3
2007 2
2006 2

Showing 10 of 13 years.

Start your 14-day trial Email me all 13 years as a PDF

Recruitment duration, a model prediction: none of the 27 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

Approved assets (10)

Shown in this order: max phase first.

Approved assets
Drug Trials
BEVACIZUMAB 5
Ranibizumab 4
AFLIBERCEPT 2
Aflibercept and ranibizumab 1
Aflibercept Injection 1

Showing 5 of 10 approved assets.

Start your 14-day trial Email me all 10 approved assets as a PDF

Journals published in (1)

Journals published in
Journal Publications
Arquivos brasileiros de oftalmologia 3

Latest dated events (27)

Shown in this order: newest first.

Latest dated events
Date Event Source
2017-09-01 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2017-09-01 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2017-08-01 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2017-07-01 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2017-05-01 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))

Showing 5 of 27 events.

Start your 14-day trial Email me all 27 events as a PDF

Biomarker capability evidence (4)

Shown in this order: tier desc, then gene symbol.

Biomarker capability evidence
Gene Role Evidence
ERG Trial sponsor Named in trial inclusion criteria
KCNH2 Trial sponsor Named in trial inclusion criteria
ERG Trial sponsor Mentioned in trial text
KCNH2 Trial sponsor Mentioned in trial text

Not on this page

Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, sponsor delivery record, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, organization relationships, clia clinical laboratory certificates, and biomarkers this organization publishes on.